Medicine
Volume 37, Issue 3 , Pages 143-148 , March 2009

Inherited haemolytic anaemias

References 

  1. In:  Jamieson DT,  Breman JG,  Measham AR editor. Priorities in health. Washington DC, USA: The World Bank; 2006;
  2. Department of Health. NHS Sickle cell and thalassaemia screening programme. London: Stationery Office. Also available at: http://www.sickleandthal.org.uk (accessed 26.11.08).
  3. Serjeant GR, Serjeant BE. Sickle cell disease. 3rd edn.. Oxford: Oxford University Press; 2001;
  4. Brozovic M, Davies SC, Brownell AI. Acute admissions of patients with sickle cell disease who live in Britain. BMJ. 1987;294:1206–1208
  5. BCSH guidelines for the prevention and treatment of infection in patients with absent or dysfunctional spleens. BMJ. 1996;312:430–434
  6. Koshy M, Weiner SJ, Miller ST, et al. Surgery and anesthesia in sickle cell disease. Cooperative study of sickle cell diseases. Blood. 1995;86:3676–3684
  7. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–1644
  8. Lucas, S.B., Mason, D.G., Mason, M, and Weyman, D. A sickle crisis? A report of the National Confidential Enquiry into Patient Outcome and Death. London; 2008.
  9. Steinberg MH, Barton F, Castro O, et al. Effects of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. J Am Med Assoc. 2003;289:1645–1651
  10. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332:1317–1322
  11. Cappellini M-D, Cohen A, Eleftheriou A, et al. Guidelines for the management of thalassaemia. 2nd edn.. Cyprus: Thalassaemia International Federation Nicosia; 2007;
  12. Weatherall DJ, Clegg JB. The thalassaemia syndromes. 4th edn.. Oxford: Blackwell Sciences; 2001;
  13. Cazzola M, De Stefano P, Ponchio L, et al. Relationship between transfusion regime and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol. 1995;89:473–478
  14. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876–1884
  15. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassaemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–1193
  16. De Sanctis V, Pintor C. Italian working group on endocrine complications in non-endocrine diseases. Multicentre study on endocrine complications in thalassaemia major. Clin Endocrinol. 1995;42:581–586
  17. Jensen CE, Tuck SM, Agnew JE, et al. High prevalence of low bone mass in thalassaemia major. Br J Haematol. 1998;103:911–915
  18. UK Thalassaemia Society. Standards for the clinical care of children and adults with thalassaemia in the UK, 2nd edn. London; 2008.
  19. Hough RE, Kelly R, Nakielny R, et al. Extramedullary haemopoiesis in haemoglobin E/beta-thalassaemia. Br J Haematol. 2003;123:738–744
  20. Sickle Cell Society. Standards for the clinical care of adults with sickle cell disease in the UK. London; 2008.
  21. NHS Sickle Cell and Thalassaemia screening programme . Sickle cell diseases in childhood – standards and guidelines for clinical care, London. Also available at: http://www.sickleandthal.org.uk/publications.htm2006;(accessed 26.11.08)
  22. Tse WT, Lux SE. Red blood cell membrane disorders. Br J Haematol. 1999;104:2–13
  23. Summerfield GP, Wyatt GP. Human parvovirus infection revealing hereditary spherocytosis. Lancet. 1985;2:1070
  24. Bolton-Maggs PH, Stevens RF, Dodd NJ, et al. Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol. 2004;126:455–474
  25. Weatherall DJ. Genetic variation and susceptibility to infection: the red cell and malaria. Br J Haematol. 2008;141:276–286
  26. Betke K, Beutler E, Brewer GJ, et al. Standardization of procedures for the study of glucose-6-phosphate dehydrogenase. WHO technical report serial No. 366. Geneva; 1967.
  27. Beutler E. G6PD deficiency. Blood. 1994;84:8613–8636
  28. Gibbs WN, Gray R, Lowry M. Glucose-6-phosphate dehydrogenase deficiency and neonatal jaundice in Jamaica. Br J Haematol. 1979;43:263
  29. Oski FA, Marshall BE, Cohen PJ, et al. The role of the left-shifted or right-shifted oxygen hemoglobin equilibrium curve. Ann Intern Med. 1971;74:44–46
  30. Ferreira P, Morais L, Costa R, et al. Hydrops fetalis associated with eryhtrocyte pyruvate kinase deficiency. Eur J Pediatr. 2000;159:481–482

PII: S1357-3039(09)00003-6

doi: 10.1016/j.mpmed.2009.01.002

Medicine
Volume 37, Issue 3 , Pages 143-148 , March 2009

Article Tools